Protocols · Growth Hormone
Dosage and protocol information sourced exclusively from PeptideDosages.com.
Read this first
Dosage and protocol figures on this page are reproduced only from the matching PeptideDosages.com protocol. The 3 ml table is arithmetic based on those source amounts and the listed vial sizes. Educational research only — not instructions or medical advice.
The dosage amounts and schedules below come only from PeptideDosages.com. Syringe-unit figures are mathematical conversions of those source amounts using exactly 3 ml of bacteriostatic water. Educational reference only — not instructions or medical advice.
AOD-9604 · 2 mg Vial
AOD-9604 is dosed at 300 mcg–500 mcg daily via subcutaneous injection in educational protocols.
| Week | Daily Dose (mcg) |
|---|---|
| Weeks 1–4 | 300 mcg |
| Weeks 5–12 | 500 mcg |
5 mg + 3 ml = 1.67 mg/ml. Choose your vial strength to update the units below.
| Source dose | U-100 syringe |
|---|---|
| 300 mcg | 18 units |
| 500 mcg | 30 units |
AOD-9604, also known as anti-obesity drug 9604, is a human growth hormone fragment (PMID 16625817, PMID 41966639). Peptides are short chains of amino acids, occupying a unique pharmacological space between small-molecule drugs and large proteins (PMID 41966639).
It is included among peptides that are covered by the World Anti-Doping Agency's list of prohibited substances due to their potential performance-enhancing properties (PMID 26578461, PMID 24906629).
AOD-9604 is a growth hormone secretagogue (PMID 41490200) and has been described as increasing adipose tissue (fat) breakdown (PMID 16625817). It is also noted for activating IGF-1 signaling and satellite cell repair (PMID 41490200).
AOD-9604 was undergoing Phase IIa clinical trials for the potential treatment of obesity by February 2002 (PMID 15134286). It has been listed among drugs undergoing clinical development for anti-obesity therapy (PMID 16625817). Its development for obesity treatment has been tracked in clinical trial gateways in 2003 (PMID 14685303, PMID 14571286).
Despite its presence in clinical trials for obesity, rigorous human safety data for many unapproved peptides, including AOD-9604, are scarce, and potential for harm to patients exists (PMID 41966639). There is a general lack of clinical trials for therapeutic peptides in orthopaedics, even though preclinical studies are promising (PMID 41490200).
While many unapproved peptides show favorable tissue repair and metabolic outcomes in animal models, human safety data for these compounds are scarce (PMID 41966639). The use of such peptides, including AOD-9604, is rapidly expanding in sports medicine due to patient demand for accelerated injury recovery and performance enhancement, often operating in a 'gray market' outside regulatory oversight (PMID 41966639).
The World Anti-Doping Agency considers AOD-9604 a doping agent, requiring analytical strategies for its detection in human blood or urine for sports drug testing (PMID 24906629, PMID 26578461). For analytical purposes, storing urine samples at -20°C was found to be an appropriate temperature for peptide stability in sports drug testing (PMID 26578461).
Summarised from the PubMed abstracts listed above. Educational reference only — not medical advice or instructions.
Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.
Verified suppliers
We are an independent publication — we sell nothing, hold no stock and take no payment. When you have finished reading, these are the suppliers we have checked for lot-matched third-party certificates of analysis.
1 · Plan the bench work
Work out reconstitution volumes and concentrations before ordering, so you buy the vial size your protocol actually needs.
Reconstitution calculator2 · Check the paperwork
Only use material released with a lot-matched third-party certificate of analysis.
Batch certificates3 · Verified suppliers
How we verify, what each supplier publishes and which regions they serve.
Supplier directoryOutbound supplier links are marked nofollow/sponsored. Compounds discussed are laboratory research reagents, not medicines. Listing is not an endorsement or medical advice.
Peptide Intel Hub is an independent educational publication. We are not affiliated with, owned by, or the same company as Biomech Peptides and Regena.app (biomechpeptides.com / regena.app). We do not sell, supply, ship or take payment for any compound. Because readers regularly ask where compounds discussed in published studies can be sourced for laboratory work, we list Biomech Peptides and Regena.app as suppliers we have verified and trust — every batch is released with a lot-matched third-party certificate of analysis (HPLC purity and mass-spectrometry identity). Outbound links are marked nofollow/sponsored and are provided to help readers, not to sell.
